Literature DB >> 28520401

Identification of GalNAc-Conjugated Antisense Oligonucleotide Metabolites Using an Untargeted and Generic Approach Based on High Resolution Mass Spectrometry.

Christophe Husser1, Andreas Brink1, Manfred Zell1, Martina B Müller1, Erich Koller1, Simone Schadt1.   

Abstract

Antisense oligonucleotides linked by phosphorothioates are an important class of therapeutics under investigation in various pharmaceutical companies. Antisense oligonucleotides may be coupled to high-affinity ligands (triantennary N-acetyl galactosamine = GalNAc) for hepatocyte-specific asialoglycoprotein receptors (ASGPR) to enhance uptake to hepatocytes and to increase potency. Since disposition and biotransformation of GalNAc-conjugated oligonucleotides is different from unconjugated oligonucleotides, appropriate analytical methods are required to identify main cleavage sites and degradation products of GalNAc conjugated and unconjugated oligonucleotides in target cells. A highly sensitive method was developed to identify metabolites of oligonucleotides using capillary flow liquid chromatography with column switching coupled to a high resolution Orbitrap Fusion mass spectrometer. Detection of GalNAc-conjugated oligonucleotides and their metabolites was achieved by combining full scan MS with two parallel MS2 experiments, one data-dependent scan and an untargeted MS2 experiment (all ion fragmentation) applying high collision energy. In the all ion fragmentation scan, a diagnostic fragment originating from the phosphorothioate backbone (O2PS-: m/z 94.936) was formed efficiently upon collisional activation. Based on this fragment an accurate determination of metabolites of oligonucleotides was achieved, independent of their sequence or conjugation in an untargeted but highly selective manner. The method was effectively applied to investigate uptake and metabolism of GalNAc-conjugated oligonucleotides in incubations of primary rat hepatocytes; the elucidation of expected and unexpected degradation products was achieved in subnanomolar range.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28520401     DOI: 10.1021/acs.analchem.7b01244

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  10 in total

1.  Investigating discovery strategies and pharmacological properties of stereodefined phosphorodithioate LNA gapmers.

Authors:  Jörg Duschmalé; Adrian Schäublin; Erik Funder; Steffen Schmidt; Łukasz J Kiełpiński; Helle Nymark; Klaus Jensen; Troels Koch; Martina Duschmalé; Erich Koller; Marianne Ravn Møller; Simone Schadt; Christophe Husser; Andreas Brink; Sabine Sewing; Tanja Minz; Jesper Wengel; Konrad Bleicher; Meiling Li
Journal:  Mol Ther Nucleic Acids       Date:  2022-06-22       Impact factor: 10.183

2.  RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.

Authors:  Ai-Ming Yu; Young Hee Choi; Mei-Juan Tu
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

3.  GalNAc Conjugation Attenuates the Cytotoxicity of Antisense Oligonucleotide Drugs in Renal Tubular Cells.

Authors:  Sabine Sewing; Marcel Gubler; Régine Gérard; Blandine Avignon; Yasmin Mueller; Annamaria Braendli-Baiocco; Marielle Odin; Annie Moisan
Journal:  Mol Ther Nucleic Acids       Date:  2018-11-20

4.  Metabolite Profiling of the Antisense Oligonucleotide Eluforsen Using Liquid Chromatography-Mass Spectrometry.

Authors:  Jaeah Kim; Babak Basiri; Chopie Hassan; Carine Punt; Erik van der Hage; Cathaline den Besten; Michael G Bartlett
Journal:  Mol Ther Nucleic Acids       Date:  2019-07-22       Impact factor: 8.886

5.  Natural polyphenol assisted delivery of single-strand oligonucleotides by cationic polymers.

Authors:  Wanwan Shen; Ruojun Wang; Qianqian Fan; Yiwen Li; Yiyun Cheng
Journal:  Gene Ther       Date:  2020-05-04       Impact factor: 5.250

6.  Novel advances in biotransformation and bioactivation research - 2020 year in review.

Authors:  S Cyrus Khojasteh; Upendra A Argikar; James P Driscoll; Carley J S Heck; Lloyd King; Klarissa D Jackson; Wenying Jian; Amit S Kalgutkar; Grover P Miller; Valerie Kramlinger; Ivonne M C M Rietjens; Aaron M Teitelbaum; Kai Wang; Cong Wei
Journal:  Drug Metab Rev       Date:  2021-06-24       Impact factor: 6.984

Review 7.  Oligonucleotides Isolation and Separation-A Review on Adsorbent Selection.

Authors:  Sylwia Studzińska; Łukasz Nuckowski; Bogusław Buszewski
Journal:  Int J Mol Sci       Date:  2022-08-23       Impact factor: 6.208

8.  Application of Locked Nucleic Acid Oligonucleotides for siRNA Preclinical Bioanalytics.

Authors:  Mai B Thayer; Julie M Lade; David Doherty; Fang Xie; Babak Basiri; Omar S Barnaby; Noor S Bala; Brooke M Rock
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

9.  In vitro and in vivo properties of therapeutic oligonucleotides containing non-chiral 3' and 5' thiophosphate linkages.

Authors:  Jörg Duschmalé; Henrik Frydenlund Hansen; Martina Duschmalé; Erich Koller; Nanna Albaek; Marianne Ravn Møller; Klaus Jensen; Troels Koch; Jesper Wengel; Konrad Bleicher
Journal:  Nucleic Acids Res       Date:  2020-01-10       Impact factor: 16.971

10.  Introducing an In Vitro Liver Stability Assay Capable of Predicting the In Vivo Pharmacodynamic Efficacy of siRNAs for IVIVC.

Authors:  Babak Basiri; Fang Xie; Bin Wu; Sara C Humphreys; Julie M Lade; Mai B Thayer; Pam Yamaguchi; Monica Florio; Brooke M Rock
Journal:  Mol Ther Nucleic Acids       Date:  2020-07-10       Impact factor: 8.886

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.